These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 33316353)

  • 1. Conditional activation of an HIV-1 protease attenuated mutant by a leucine zipper dimerization motif.
    Yu FH; Huang KJ; Wang CT
    Virus Res; 2021 Apr; 295():198258. PubMed ID: 33316353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 protease with leucine zipper fused at N-terminus exhibits enhanced linker amino acid-dependent activity.
    Yu FH; Wang CT
    Retrovirology; 2018 Apr; 15(1):32. PubMed ID: 29655366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-Terminal HIV-1 Transframe p6* Tetrapeptide Blocks Enhanced Gag Cleavage Incurred by Leucine Zipper Replacement of a Deleted p6* Domain.
    Yu FH; Huang KJ; Wang CT
    J Virol; 2017 May; 91(10):. PubMed ID: 28250114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 reverse transcriptase stability correlates with Gag cleavage efficiency: reverse transcriptase interaction implications for modulating protease activation.
    Hsieh SH; Yu FH; Huang KJ; Wang CT
    J Virol; 2023 Sep; 97(9):e0094823. PubMed ID: 37671867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Placement of leucine zipper motifs at the carboxyl terminus of HIV-1 protease significantly reduces virion production.
    Pan YY; Wang SM; Huang KJ; Chiang CC; Wang CT
    PLoS One; 2012; 7(3):e32845. PubMed ID: 22396796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gag-Pol Transframe Domain p6* Is Essential for HIV-1 Protease-Mediated Virus Maturation.
    Yu FH; Chou TA; Liao WH; Huang KJ; Wang CT
    PLoS One; 2015; 10(6):e0127974. PubMed ID: 26030443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of the Gag-Pol transframe domain p6* and its coding sequence to morphogenesis and replication of human immunodeficiency virus type 1.
    Paulus C; Ludwig C; Wagner R
    Virology; 2004 Dec; 330(1):271-83. PubMed ID: 15527852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of reduced gag cleavage efficiency on HIV-1 Gag-Pol package.
    Lin YR; Chu SM; Yu FH; Huang KJ; Wang CT
    BMC Microbiol; 2022 Apr; 22(1):94. PubMed ID: 35395730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling the full length HIV-1 Gag polyprotein reveals the role of its p6 subunit in viral maturation and the effect of non-cleavage site mutations in protease drug resistance.
    Su CT; Kwoh CK; Verma CS; Gan SK
    J Biomol Struct Dyn; 2018 Dec; 36(16):4366-4377. PubMed ID: 29237328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient particle production by minimal Gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain.
    Accola MA; Strack B; Göttlinger HG
    J Virol; 2000 Jun; 74(12):5395-402. PubMed ID: 10823843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interplay between protease and reverse transcriptase dimerization in a model HIV-1 polyprotein.
    Chagas BCA; Zhou X; Guerrero M; Ilina TV; Ishima R
    Protein Sci; 2024 Jul; 33(7):e5080. PubMed ID: 38896002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response.
    Ho SK; Coman RM; Bunger JC; Rose SL; O'Brien P; Munoz I; Dunn BM; Sleasman JW; Goodenow MM
    Virology; 2008 Sep; 378(2):272-81. PubMed ID: 18599104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding of Clinical Inhibitors to a Model Precursor of a Rationally Selected Multidrug Resistant HIV-1 Protease Is Significantly Weaker Than That to the Released Mature Enzyme.
    Park JH; Sayer JM; Aniana A; Yu X; Weber IT; Harrison RW; Louis JM
    Biochemistry; 2016 Apr; 55(16):2390-400. PubMed ID: 27039930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of human immunodeficiency virus type 1 transframe protein p6* mutations on viral protease-mediated Gag processing.
    Chiu HC; Wang FD; Chen YA; Wang CT
    J Gen Virol; 2006 Jul; 87(Pt 7):2041-2046. PubMed ID: 16760407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human immunodeficiency virus type 1 and related primate lentiviruses engage clathrin through Gag-Pol or Gag.
    Popov S; Strack B; Sanchez-Merino V; Popova E; Rosin H; Göttlinger HG
    J Virol; 2011 Apr; 85(8):3792-801. PubMed ID: 21289110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of protease cleavage sites within and flanking human immunodeficiency virus type 1 transframe protein p6* for spatiotemporal regulation of protease activation.
    Ludwig C; Leiherer A; Wagner R
    J Virol; 2008 May; 82(9):4573-84. PubMed ID: 18321978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Context surrounding processing sites is crucial in determining cleavage rate of a subset of processing sites in HIV-1 Gag and Gag-Pro-Pol polyprotein precursors by viral protease.
    Lee SK; Potempa M; Kolli M; Özen A; Schiffer CA; Swanstrom R
    J Biol Chem; 2012 Apr; 287(16):13279-90. PubMed ID: 22334652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human immunodeficiency virus (HIV) type 1 transframe protein can restore activity to a dimerization-deficient HIV protease variant.
    Dautin N; Karimova G; Ladant D
    J Virol; 2003 Aug; 77(15):8216-26. PubMed ID: 12857890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flexible catalytic site conformations implicated in modulation of HIV-1 protease autoprocessing reactions.
    Huang L; Li Y; Chen C
    Retrovirology; 2011 Oct; 8():79. PubMed ID: 21985091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
    Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
    Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.